AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 91 min read$IONS

BENNETT C FRANK sold $463K of IONS

BENNETT C FRANK (EVP, Chief Scientific Officer) sold 5,536 shares of IONIS PHARMACEUTICALS INC (IONS) at $83.58 ($0.46M total) on 2026-07-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · BENNETT C FRANK
Published Jul 9, 2026, 11:26 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 9, 2026, 11:29 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$IONS
Neutral
high confidence
Mentioned
$IONS
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IONSNeutralLow
01

Why it matters

This provides a datapoint on insider activity but does not introduce new company-specific fundamentals or catalysts.

02

Market read

Traders may monitor insider activity, but the 10b5-1 structure and lack of new fundamentals suggest limited trading edge.

03

What to watch

The filing does not include any new clinical, regulatory, or financial guidance; without those, the trading signal is weak.

Relevance 3/10Novelty 3/10Timing: Filed July 9, transaction dated July 7 (10b5-1 sale).

Background

The article is a SEC Form 4 insider transaction disclosure for Ionis Pharmaceuticals, reported by an EVP and Chief Scientific Officer.

Company-level read

Ticker impact

$IONSNeutralHigh confidence
Context

Ionis Pharmaceuticals disclosed an EVP Chief Scientific Officer open-market sale of 5,536 shares at $83.5790 on July 7 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; treat as informational rather than a directional signal.

Evidence & confidence

The filing is a Form 4 insider transaction and explicitly states a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

Sector

Minimal read-across to biotech sector fundamentals; this is company-specific insider trading disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • issuer
    IONIS PHARMACEUTICALS INC

    Company whose Form 4 insider transaction was filed.

  • insider
    BENNETT C FRANK

    EVP, Chief Scientific Officer who sold shares in an open-market transaction under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 8
$IONSMedAI 8/10

Ionis (IONS) Q2 2026 Earnings Call Transcript

Ionis Pharmaceuticals (IONS) reported Q2 2026 total revenue of $268 million, up 56% excluding a one-time Sapablursen payment. Commercial revenue was $119 million, driven by DAWNZERA sales of $26 million (+63% QoQ). 2026 guidance: $875 million to $900 million revenue and non-GAAP operating loss of $425 million to $475 million. Cash was $2.1 billion.

aol.com7 min
JUL 30
$IONSMed

Ionis Pharmaceuticals: Q2 Earnings Snapshot

Ionis Pharmaceuticals (IONS) reported a Q2 loss of $115 million, or 69 cents per share. Adjusted for stock option expense, the loss was 43 cents per share. Revenue was $268 million, above Street expectations of $190.7 million, according to Zacks.

aol.com2 min
JUL 29
$IONSMedAI 8/10

IONIS PHARMACEUTICALS INC (IONS): Results of Operations and Financial Condition

IONIS PHARMACEUTICALS INC (IONS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ef20078953_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Ionis reports second quarter 2026 financial results and highlights progress on key programs - TRYNGOLZA ® (olezarsen) demonstrating early sHTG launch momentum, underscoring multi-billion-dollar revenue potential in large p

SEC EDGAR 8-K6 min
JUL 25
$IONSMed

Ionis Pharmaceuticals (IONS) Trial Setback Sparks Scrutiny, Is The 38% Undervaluation Case Still Credible?

Ionis Pharmaceuticals (IONS) said its late-stage CARDIO TTRansform trial of eplontersen with AstraZeneca did not meet the primary efficacy endpoint, prompting a sharp share drop and a shareholder investigation. The stock was down 26.1% over 30 days and 29.0% YTD. The article cites a $92 fair value versus $56.55 last close and discusses valuation metrics including P/S 8.8x.

simplywall.st5 min
JUL 23
$IONSMed

Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% - HBSS

Ionis Pharmaceuticals (NASDAQ: IONS) shares fell about 23% on July 9, 2026 after it and AstraZeneca reported the Phase 3 CARDIO-TTRansform trial of eplontersen for ATTR-CM did not meet the primary efficacy endpoint. The company said adding eplontersen was not statistically beneficial in a contemporary standard-of-care population. Hagens Berman opened an investor-fraud investigation into trial transparency.

prnewswire.com3 min